Mission Wealth Management LP Sells 215 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mission Wealth Management LP trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,670 shares of the company’s stock after selling 215 shares during the quarter. Mission Wealth Management LP’s holdings in IDEXX Laboratories were worth $691,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Plato Investment Management Ltd grew its position in IDEXX Laboratories by 57.2% during the 4th quarter. Plato Investment Management Ltd now owns 2,252 shares of the company’s stock worth $934,000 after acquiring an additional 819 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in IDEXX Laboratories during the 4th quarter worth approximately $97,000. SRS Capital Advisors Inc. grew its position in IDEXX Laboratories by 363.3% during the 4th quarter. SRS Capital Advisors Inc. now owns 366 shares of the company’s stock worth $151,000 after acquiring an additional 287 shares during the last quarter. Smartleaf Asset Management LLC grew its position in IDEXX Laboratories by 10.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 635 shares of the company’s stock worth $262,000 after acquiring an additional 58 shares during the last quarter. Finally, Middleton & Co. Inc. MA grew its position in IDEXX Laboratories by 98.1% during the 4th quarter. Middleton & Co. Inc. MA now owns 12,305 shares of the company’s stock worth $5,087,000 after acquiring an additional 6,095 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent analyst reports. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, February 27th. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Up 1.0 %

NASDAQ IDXX opened at $441.61 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $574.94. The firm has a market capitalization of $35.92 billion, a PE ratio of 41.39, a P/E/G ratio of 3.41 and a beta of 1.37. The stock’s 50 day moving average is $436.35 and its 200 day moving average is $450.43.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.